Frontlight ResearchEarly access
Active, not recruitingNo phase
Transcranial Ultrasound Stimulation as a Neuromodulation Therapy for Craving and Relapse Behaviors in Alcohol Use Disorder.
Key facts
- Who runs it
- Shanghai Mental Health Center
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 40 people, planned
- Started
- 20 Mar 2025
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Shame TUS-vmPFC
- Active TUS-vmPFC
- Record updated
- 13 January 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Education level of junior high school or above, capable of completing questionnaires and behavioral tests
- Aged 18-60 years
- Meet DSM-5 diagnostic criteria for Alcohol Use Disorder
- No abnormal findings on physical examination
- Agree to participate in follow-up assessments
- No contraindications for MRI scanning
Who cannot take part
- Prior tDCS or TMS treatment within the past 3 months
- Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy)
- Severe somatic diseases or major organ dysfunction
- Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders)
- Have impaired intelligence (Intelligence Quotient<70)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the efficacy of transcranial ultrasound stimulation in reducing cravings and preventing relapse in individuals with alcohol use disorders. Utilizing a double-blind design, participants will be randomly assigned to receive either active accelerated transcranial ultrasound stimulation or a sham treatment.
The 2 groups in the trial
- Intervention groupTreatment being tested
The active group will receive active transcranial ultrasound stimulation.
Treatment: Active TUS-vmPFC
- Control groupSham treatment, for comparison
The sham group will receive shame transcranial ultrasound stimulation.
Treatment: Shame TUS-vmPFC
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 January 2026